The company is the only biopharma focused exclusively on the development and commercialisation of new treatment options for people with hemophilia.
Butler has more than 20 years experience in the field of commercialisation for innovative therapies.
He replaces Michael Griffith, who will become chief scientific officer, and will remain as president at Inspiration.
Valeant, Rentschler, Celgene, MannKind, and Syngene are among those welcoming new leaders for 2016. Oh, and Turing...